Syneos Health - SYNH Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYNH shares.
View SYNH analyst ratings or view top-rated stocks.

10 equities research analysts have issued 1-year price targets for Syneos Health's stock. Their SYNH share price forecasts range from $55.00 to $105.00. On average, they anticipate the company's stock price to reach $79.60 in the next year. This suggests a possible upside of 55.2% from the stock's current price.
View analysts price targets for SYNH or view top-rated stocks among Wall Street analysts.

Syneos Health's stock was trading at $102.68 at the beginning of 2022. Since then, SYNH stock has decreased by 50.0% and is now trading at $51.30.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our SYNH earnings forecast.

Syneos Health, Inc. (NASDAQ:SYNH) released its quarterly earnings data on Tuesday, August, 2nd. The company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. The business earned $1.36 billion during the quarter, compared to analyst estimates of $1.39 billion. Syneos Health had a trailing twelve-month return on equity of 14.04% and a net margin of 5.13%. The business's quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.86 EPS.

Syneos Health issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of $4.97-$5.11 for the period, compared to the consensus earnings per share estimate of $5.11. The company issued revenue guidance of $5.44 billion-$5.54 billion, compared to the consensus revenue estimate of $5.66 billion.

322 employees have rated Syneos Health Chief Executive Officer Alistair Macdonald on Glassdoor.com. Alistair Macdonald has an approval rating of 82% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Block (SQ), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include First Hawaiian Bank (0.01%). Insiders that own company stock include Alistair Macdonald, Donna Hildebrand Kralowetz, International Corp/Ma Advent, Jason M Meggs, John L Maldonado, John M Dineen, Jonathan Olefson, Linda S Harty, Mark E Jagiela, Matthew E Monaghan, Matthew E Monaghan, Michael Lee Brooks, Michelle Keefe, Paul Colvin, Robert Parks, Thomas H Lee Advisors, Llc and Tom Allen.
View institutional ownership trends.

Shares of SYNH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYNH stock can currently be purchased for approximately $51.30.

Syneos Health (NASDAQ:SYNH) has a market capitalization of $5.27 billion and generates $5.21 billion in revenue each year. The company earns $234.83 million in net income (profit) each year or $2.66 on an earnings per share basis.

The company employs 28,000 workers across the globe.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The official website for the company is www.syneoshealth.com. The company can be reached via phone at (919) 876-9300, via email at investor.relations@syneoshealth.com, or via fax at 919-876-9360.